Literature DB >> 15531466

Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia.

Markus Ritter, Theo Daniel Kim, Petra Lisske, Christian Thiede, Markus Schaich, Andreas Neubauer.   

Abstract

Reports on the prognostic impact of mutations in the RAS proto-oncogenes in patients with acute myeloid leukemia (AML) are conflicting. A peptide nucleic acid (PNA)-based technique was used on 232 AML samples to detect point mutations of the hotspots in N-RAS and K-RAS. No significant correlations between RAS mutations and clinical features, karyotype or FLT3 were found.

Entities:  

Mesh:

Year:  2004        PMID: 15531466

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

1.  RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Hirozumi Sano; Akira Shimada; Tomohiko Taki; Chisato Murata; Myoung-Ja Park; Manabu Sotomatsu; Ken Tabuchi; Akio Tawa; Ryoji Kobayashi; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2012-03-10       Impact factor: 2.490

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

Review 3.  Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives.

Authors:  Felicitas Thol; Arnold Ganser
Journal:  Front Med China       Date:  2010-12-01

4.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

5.  Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia.

Authors:  Mi-Jung Park; Soon-Ho Park; Pil-Whan Park; Yiel-Hea Seo; Kyung-Hee Kim; Ji-Hun Jeong; Moon Jin Kim; Jeong-Yeal Ahn; Jae Hoon Lee; Jinny Park; Junshik Hong
Journal:  Int J Hematol       Date:  2013-10-09       Impact factor: 2.490

6.  Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

Authors:  Andreas Neubauer; Kati Maharry; Krzysztof Mrózek; Christian Thiede; Guido Marcucci; Peter Paschka; Robert J Mayer; Richard A Larson; Edison T Liu; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

7.  High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations.

Authors:  Bjørnar Gilje; Reino Heikkilä; Satu Oltedal; Kjersti Tjensvoll; Oddmund Nordgård
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

8.  The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine.

Authors:  Ebtesam I Ahmad; Heba H Gawish; Nashwa Ma Al Azizi; Ashraf M Elhefni
Journal:  Onco Targets Ther       Date:  2011-07-15       Impact factor: 4.147

9.  Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.

Authors:  Afia Muhammad Akram; Asma Chaudhary; Humera Kausar; Fayez Althobaiti; Afshan Syed Abbas; Zawar Hussain; Naz Fatima; Erum Zafar; Wajiha Asif; Umair Afzal; Zoufishan Yousaf; Amjad Zafar; Steve M Harakeh; Samina Qamer
Journal:  Saudi J Biol Sci       Date:  2021-05-06       Impact factor: 4.219

10.  N-ras mutation detection by pyrosequencing in adult patients with acute myeloid leukemia at a single institution.

Authors:  Ji Hun Jeong; Soon Ho Park; Mi Jung Park; Moon Jin Kim; Kyung Hee Kim; Pil Whan Park; Yiel Hea Seo; Jae Hoon Lee; Jinny Park; Junshik Hong; Jeong Yeal Ahn
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.